| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Eptinezumab (anti-CGRP)
CAS:1644539-04-7
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0 EU/mg; Human Package:5mg Remarks:K10708
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Eptinezumab
CAS:1644539-04-7
Purity:95% Package:100ug;500ug;1mg
|
|
| | Eptinezumab Basic information |
| Product Name: | Eptinezumab | | Synonyms: | Eptinezumab;Research Grade Eptinezumab(DHC22403);Eptinezumab (anti-CGRP);Research Grade Eptinezumab | | CAS: | 1644539-04-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Eptinezumab Structure]() |
| | Eptinezumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Eptinezumab Usage And Synthesis |
| Uses | Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults[1][2]. | | References | [1] Dhillon S. Eptinezumab: First Approval.Drugs. 2020;80(7):733-739. DOI:10.1007/s40265-020-01300-4
[2] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Eptinezumab. 2021 Jul 9. PMID:34292696 |
| | Eptinezumab Preparation Products And Raw materials |
|